A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.
Rey V, Tornín J, Alba-Linares JJ, Robledo C, Murillo D, Rodríguez A, Gallego B, Huergo C, Viera C, Braña A, Astudillo A, Heymann D, Szuhai K, Bovée JVMG, Fernández AF, Fraga MF, Alonso J, Rodríguez R.
Rey V, et al. Among authors: murillo d.
EBioMedicine. 2024 Apr;102:105090. doi: 10.1016/j.ebiom.2024.105090. Epub 2024 Mar 27.
EBioMedicine. 2024.
PMID: 38547578
Free PMC article.